Whole-Exome Sequencing in a South American Cohort Links ALDH1A3, FOXN1 and Retinoic Acid Regulation Pathways to Autism Spectrum Disorders

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1371/journal.pone.0135927

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:22856990

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
RESEARCH ARTICLE

Whole-Exome Sequencing in a South American Cohort Links ALDH1A3, FOXN1 and Retinoic Acid Regulation Pathways to Autism Spectrum Disorders

Oscar A. Moreno-Ramos1, Ana María Olivares2, Neena B. Haider2, Liga Colombiana de Autismo3¶, María Claudia Lattig1*

1 Departamento de Ciencias Biológicas, Facultad de Ciencias, Universidad de los Andes, Bogotá D.C., Colombia, 2 Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA, United States of America, 3 Liga Colombiana de Autismo (LICA), Bogotá D.C., Colombia

¶ Membership of the Liga Colombiana de Autismo is listed in the Acknowledgments.
*
mlattig@uniandes.edu.co

Abstract

Autism spectrum disorders (ASDs) are a range of complex neurodevelopmental conditions principally characterized by dysfunctions linked to mental development. Previous studies have shown that there are more than 1000 genes likely involved in ASD, expressed mainly in brain and highly interconnected among them. We applied whole exome sequencing in Colombian—South American trios. Two missense novel SNVs were found in the same child: ALDH1A3 (RefSeq NM_000693: c.1514T>C (p.I505T)) and FOXN1 (RefSeq NM_003593: c.146C>T (p.S49L)). Gene expression studies reveal that Aldh1a3 and Foxn1 are expressed in ~E13.5 mouse embryonic brain, as well as in adult piriform cortex (PC; ~P30). Conserved Retinoic Acid Response Elements (RAREs) upstream of human ALDH1A3 and FOXN1 and in mouse Aldh1a3 and Foxn1 genes were revealed using bioinformatic approximation. Chromatin immunoprecipitation (ChIP) assay using Retinoid Acid Receptor B (Rarb) as the immunoprecipitation target suggests RA regulation of Aldh1a3 and Foxn1 in mice. Our results frame a possible link of RA regulation in brain to ASD etiology, and a feasible non-additive effect of two apparently unrelated variants in ALDH1A3 and FOXN1 recognizing that every result given by next generation sequencing should be cautiously analyzed, as it might be an incidental finding.

Introduction

Autism spectrum disorders (ASD) are a range of complex neurodevelopmental conditions characterized by dysfunctions in mental development [1]. At the same time, it has been hypothesized that ASD are a group of continuous disorders instead of a single discrete disorder [2], explaining why ASD patient symptomatology is so variable. Although prevalence of ASD has increased worldwide [3], in Colombia there are no official reports regarding its prevalence.
A recent study has shown that ASD heritability is calculated closely to 50% [4] (lower than the ~90% previously estimated [2,5]) leading to higher environmental factor’s impact on the occurrence of the disorder. In fact, no clear environmental factors that have been unfolded since the recurrence of ASD does not change statistically between dizygotic twins and complete siblings [4].

Most of our understanding of the molecular basis of ASD comes from reports of rare copy number variants (CNVs) [6–8] and the discovery of *de novo* single nucleotide variants (SNVs) using Whole Exome Sequencing (WES) [9–13] or Whole Genome Sequencing (WGS) [14]. More than a 1000 genes are thought to be involved in ASD [15], most of them located in genes of known function and involved in pathways related to cell and neuronal development, projection, motility and proliferation; also in genes involved in spine and dendrite plasticity regulation, and gene regulation [8,15,16]. Additionally, variants affecting recurrent genes have been associated to ASD by their single impact ignoring a possible synergic impact between two or more *de novo* events in the same individual. Nonetheless, all this information has been derived mostly from Caucasian individuals. Thus, novel genes and even novel pathways involved in ASD pathogenesis might be found in understudied populations such as Colombian.

WES was applied in search of *de novo* variants that might be causative of ASD in four family trios from Colombia. Two *de novo* non-synonymous mutations affecting *ALDH1A3* (RefSeq NM_000693, MIM:600463) and *FOXN1* (RefSeq NM_003593.2, MIM:600838) genes were uncovered in the same child (FAM07). Recently, retinoic acid (RA) pathways mediated by Retinoid Orphan Receptor Alpha (RORA) have been implicated in ASD [17]. Furthermore, homozygous *ALDH1A3* missense and nonsense mutations in humans have been linked to anophthalmia and microphthalmia (MIM: 615113; A/M) with some affected individuals also exhibiting autistic traits [18–23]. Though no clear evidence supports a link between variants in *ALDH1A3* with autism, mouse studies show that lack of Aldh1a3 (Gene NC_000073.6) results in abnormal GABAergic neuronal differentiation in the forebrain basal ganglia [24]. Malfunctiions in this inhibitory system have been found to be associated to mental disorders like ASD, schizophrenia and bipolar disorder [25,26]. Moreover, failures of this enzyme in the striatum are related to elimination of dopamine receptor D2 in the nucleus accumbens [27].

Although little is known about *FOXN1*, it is essential for proper immune system function, especially in thymus development and maintenance during adulthood [28–30]. Foxn1 (Gene NC_000077.6) knockout mice (commonly known as NUDE mouse) overexpress pro-inflammatory cytokines (Specially TH1) [31]. This overexpression has also been reported in ASD children [32]. Besides T-cell immunodeficiency, mutations in *FOXN1* have also been observed together with congenital alopecia and nail dystrophy (MIM: 601705). A homozygote mutation in *FOXN1* was reported in a 15-week-old fetus with anencephaly and severe neural tube defect (MIM: 601705) [33].

As *ALDH1A3* is an enzyme responsible for Retinoic Acid (RA) synthesis, and *FOXN1* has been found to be regulated by RORA (gene involved in RA cascade) [17], together with RA’s major role in gene expression regulation during brain development [34], it was questioned if RA might possibly regulate *ALDH1A3* and *FOXN1* through RA receptors (RARs). Predicted RA Response Elements (RAREs) in the promoter regions of both genes where evaluated to be recognized by RARs, using C57BL/6J (B6) mice, in two developmental stages. Rarb (Gene NC_000080.6) was selected as the chromatin association target protein since it is known to regulate dorsal and ventral telencephalon development, hippocampal plasticity and brain barrier development [35–38].

Results indicate that Rarb regulates Aldh1a3 and Foxn1 (NC_000077.6) in adult (~P30) mice PC and in embryo (~E13.5) whole brain, as demonstrated by ChiP essay. We suspect that both variants in genes *ALDH1A3* and *FOXN1* interact in a non-additive manner, where an
epistatic interaction effect can be expected, possibly explaining the etiology in the affected child.

Methods

Ethics statement

The study presented here involves human participation and informed consent and assent. The study and consent procedure was approved by the ethical committee of Universidad de los Andes (Acta 11, 2011). Informed consent and assent was given and explained to all participants. All participants provided a written informed consent to participate in this study. Each consent was marked with a family and individual unique identifier, names and identifying information are kept securely stored. Only the principal investigator is able to recognize personal data with unique identifiers.

Animal procedures were approved by Schepens Eye Research Institute Animal Care and Use Committee (Permit number: S-309–0714) in compliance with the Animal Welfare Act Regulations.

Cohort selection

Four family trios (family ID: Fam02, Fam07, Fam09 and Fam10) referred by Liga Colombiana de Autismo (LICA) were selected to participate in the study. All individuals are from Bogotá D.C.—Colombia. Affected individuals were engaged in a series of tests-tasks to evaluate patterns and maturity of the child, interaction with parents and family patterns. Inclusion in the present study required meeting criteria for autism on the ADOS [39] and ADI-R [40] and subject were confirmed to meet DSM-V (APA, 2012) criteria for autism by trained professionals who observed and interacted with them over several visits. After psychological examination, a genetic counselor physician discarded any comorbidity with other ASD related syndrome.

DNA sample preparation, exome sequencing and analysis

DNA extraction was carried out using FlexiGene DNA kit (Qiagen, Gaithersburg, MD, USA). The extraction was carried out parting from 300uL of leucocytes following manufacturer instructions. A mean of 8.7ug of DNA per individual was sent to Otogenetics Corporation in Atlanta GA, USA. We applied WES using Agilent Sureselect All Exon V4 platform and PE100 Illumina HiSeq2000 platform to the four family trios selected (all family trios DNA samples met the quality criteria for WES by Otogenetics Corporation, Atlanta, GA—USA). Sequence reads were cleaned using the latest version of FASTX-Toolkit (V 0.0.13.2) (http://hannonlab.cshl.edu/fastx_toolkit/index.html). Sequence mapping and variant calling was carried first by mapping the short sequences using Burrows-Wheeler aligner (BWA) (from http://bio-bwa.sourceforge.net) [41] on the latest version of the human genome available at UCSC Genome Browser (HG19). SAM tools (from http://samtools.sourceforge.net) [42] and PicardTools (from http://picard.sourceforge.net) were used to manipulate and mark sequence duplicates. SNPs and small indel calling was achieved using HaplotypeCaller walker of Genome Analysis Toolkit (GATK, from http://www.broadinstitute.org/gatk/) [43,44]. Best practices of GATK were followed in order to guarantee an efficient variant calling. Annotation was performed using snpEff (Human genome reference 37.5) [45]. Putative de novo variants were identified using AWK language.
Variant prioritization and validation

After identifying all the non-inherited variants, minor allele frequency (MAF) was revised from dbSNP. Those variants that presented a MAF > 5% were discarded. Different sets of primers were manually designed to flank the variants position obtained during calling. PCR amplification protocol described in Perea, C.S. et al., 2012 was used [46]. Sanger sequencing at Macrogen, Seul—Korea; and at Universidad de los Andes’ Sanger sequencing facility (3500 Genetic Analyzer; Applied Biosystems, USA) was used to corroborate the presence of each of the variants unveiled.

After validation of each of the variants was performed, depending on the predicted impact, different bioinformatic tools were used to predict their impact. The possible effect of the synonymous variant on mRNA stability was analyzed using SilVA [47], and ESEfinder for possible de novo splicing regions [48,49]. Non-synonymous variants were analyzed using SIFT [50], PolyPhen [51] and PROVEAN [52].

Retinoic acid regulation pattern discovery

Searching for the relaxed Retinoic Acid Response Element [RARE; 5'- (A/G)G(G/T)(G/T)(G/C)A-3' motif separated by one, two or five nucleotides, which interacts with heterodimers of RARs and retinoid X receptors (RXRs)] [34,53,54], was achieved using the online interface of Patser (online site: http://stormo.wustl.edu/consensus/html/Html/main.html) [55]. Genomic region spanning 30000bp upstream to 1000bp downstream from the initial transcription site for humans and mice (Human genome build NCBI 37.5 and Mouse genome build GRCm38. p2) in both negative and positive strands was analyzed.

Animals

Pregnant females and adults were obtained under standard conditions from Jackson Laboratory and housed in vivariums at Schepens Eye Research Institute. The study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institute of Health. Tissues were collected from C57BL/6J (B6) postnatal (~P30) and from B6 embryonic (~E13.5).

Aldh1a3 and Foxn1 expression study

Transcription was observed after total RNA extraction from piriform cortex (PC) from both lobules of adult C57BL/6J (B6) brain mice (~P30), and B6 embryonic whole brain (~E13.5) using Trizol. PC was chosen since Aldh1a3 expression has been reported in this region in postnatal stages [56]. A total of 2μg of total RNA was reversed using random decamers, in independent biological triplicates using Retroscript (Ambion). PCR, using primers flanking the conserved splice regions of both genes (S2 Table), was used to check Foxn1 and Aldh1a3 transcription. PCR products were run on agarose (2%) ethidium bromide stained gel.

Chromatin immunoprecipitation

Chromatin immunoprecipitacion assay (ChIP) against RARs-RARE interaction was used to validate the bioinformatic predictions. ChIP, followed by PCR against the interaction of Rarb with the predicted RAREs, was performed as described in Haider, N.B. et al., 2009 with modifications [57]. Briefly, three adult (~P30) mice PC and three embryo (~E13.5) mouse whole brain were collected. Each sample was sonicated using three cycles. First cycle: 1s pulse’ 1s wait between pulses; total of 20 pulses. Second cycle: 19 steps of ten pulses, 1s pulse’ 1s wait between pulses, 30 seconds wait between steps; total of 190 pulses. Third cycle: 10s pulse’20s wait
between pulses; total of three pulses. Average DNA fragment size obtained was ~300bp. Ali-
quot; for Input (Positive control), Rarb antibody (SC-552, Santa Cruz Biotechnology, Inc.)
immunoprecipitation and rabbit IgG (2027, Santa Cruz Biotechnology, Inc.) (Negative control)
were taken and incubated overnight. PCR was performed using primers flanking each RARE
sequence found in mice (S3 Table), to amplify approximately 200 base pair amplicon. PCR
conditions used are previously described in Haider, N.B. et al., 2001 where an annealing tem-
perature of 58°C and 35 cycles were applied, and a dilution of 1:10 for the Input sample was
used [58]. PCR products were visualized by ethidium bromide staining.

Results
Exome sequencing, technical outcomes, variant calling and de novo variant discovery
After applying WES, a ~69.1X coverage was yielded. In average, ~228,116.1 variants per family
trio were obtained. A total of three SNVs and one Indel were validated by PCR amplification
followed by Sanger sequencing (Table 1). We observed a transversion-transition ratio of 1:2
and non-coding SNV or Indel were found in two of the families studied. None of the genes
found in this study have been reported in the 982 WES studies [9–13], or in any of the ten
WGS family trios [14] performed to date. All other NGS data is stored at the Universidad de
los Andes bioinformatic facility and it is freely available upon request.

Variant prioritization and analysis
One synonymous de novo SNV, located in NR4A2 (Table 1, RefSeq NM_006186.3, MIM:
601828; c.779G>T [p.S119]) and one de novo insertion in the ORF GAS8-AS1 (Table 1, RefSeq
NC_000016.10, MIM:605179; g.90095617_90095618insCTGCGGGGCAGC) were found in
the proband of Fam10. The possible effect of the synonymous variant on mRNA stability was
analyzed using SilVA [47], as in O’Roak, B.J. et al., 2012 another synonymous variant was
reported in this gene [10], and ESEfinder for possible de novo splicing regions [48,49], but no
effects on mRNA stability or possible new splice sites were found (Table 2). The insertion in

Table 1. Non-inherited variants found in families Fam07 y Fam10.

<table>
<thead>
<tr>
<th>Family ID</th>
<th>Gene name</th>
<th>Chr.</th>
<th>Chr. Pos.</th>
<th>Ref. Allele</th>
<th>Altern. Allele</th>
<th>A.A. Change</th>
<th>Sanger Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fam07</td>
<td>ALDH1A3</td>
<td>15</td>
<td>101454953</td>
<td>T</td>
<td>C</td>
<td>I505T</td>
<td>+</td>
</tr>
<tr>
<td>Foxn1</td>
<td>FOXN1</td>
<td>17</td>
<td>26851543</td>
<td>C</td>
<td>T</td>
<td>S49L</td>
<td>+</td>
</tr>
<tr>
<td>Fam10</td>
<td>NR4A2</td>
<td>2</td>
<td>157186342</td>
<td>C</td>
<td>A</td>
<td>S119</td>
<td>+</td>
</tr>
<tr>
<td>GAS8-AS1</td>
<td></td>
<td>16</td>
<td>90095617</td>
<td>G</td>
<td>GCTGCGGGGCAGC</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pone.0135927.t001

Table 2. Predicted impact using SIFT, PROVEAN and PolyPhen to the non-synonymous de novo Novel variants in proband from family Fam07.

<table>
<thead>
<tr>
<th>Family</th>
<th>Variant class</th>
<th>Gene</th>
<th>Software</th>
<th>SilVA</th>
<th>ESEfinder</th>
<th>PROVEAN (Cutoff&lt;2.5)</th>
<th>SIFT (Cutoff&lt;0.05)</th>
<th>PolyPhen (Cutoff&lt;0.878)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fam07</td>
<td>Non-Synonymous</td>
<td>ALDH1A3</td>
<td>NA</td>
<td>NA</td>
<td>Neutral (-0.241)</td>
<td>Tolerated (0.142)</td>
<td>Possibly Damaging (0.878)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FOXN1</td>
<td>NA</td>
<td>NA</td>
<td>Deleterious (-3.534)</td>
<td>Tolerated (0.142)</td>
<td>Possibly Damaging (0.878)</td>
<td></td>
</tr>
<tr>
<td>Fam10</td>
<td>Synonymous</td>
<td>NR4A2</td>
<td>Likely</td>
<td>Neutral (-0.241)</td>
<td>Harmful (0.006)</td>
<td>Benign (0.137)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Insertion</td>
<td>No splice site found</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pone.0135927.t002
GAS8-AS1 (Table 1) was analyzed using ESEfinder to determine if it might alter GAS8 gene (MIM:605178) splice since it is located in intron 2. ESEfinder did not show any new probable splicing site for the Indel in GAS8-AS1 or even GAS8 (Table 2).

Two non-synonymous de novo variants were uncovered in the affected child of family Fam07 within ADLH1A3 (RefSeq NM_000693: c.1514T>C (p.I505T)) and FOXN1 (RefSeq NM_003593: c.146C>T (p.S49L)) (Fig 1). SIFT predictions indicate that the FOXN1 alteration is harmful; while PolyPhen [51] and PROVEAN [52] predict that the SNV located in ADLH1A3 is deleterious (Table 2). The other two families: Fam02 and Fam09 did not reveal any de novo mutations on the affected probands. The study further focused on studying both ADLH1A3 and FOXN1 since the variants found have a potential negative impact.

RAREs prediction

After looking for the RAREs pattern using Patser in the positive and negative strands of the promoter region of genes ADLH1A3 and FOXN1 in humans, as in Aldh1a3 and Foxn1 in mice [55], four possible RAREs for ADLH1A3 and 18 for FOXN1 in humans, and ten possible RAREs for Aldh1a3 and 11 for Foxn1 in mice were found (S1 Table).

Aldh1a3 and Foxn1 expression in mice brain tissues and regulation by Rarb

According to the expression analysis performed on adult (~P30) PC and in embryo (~E13.5) whole brain, electrophoretic run indicates that both genes are transcribed in ~P30 mouse PC and in ~E13.5 mouse whole brain Fig 2A.
Chromatin Immunoprecipitation results demonstrate that Rarb binds to one predicted RARE upstream of Aldh1a3 and to two predicted RAREs upstream of Foxn1 in the adult PC (Fig 2B, Table 3) in mice. In the embryo’s stage, we observed that Rarb binds to one predicted RARE for Aldh1a3 and two for Foxn1 (Fig 2B, Table 3) in mice. These results indicate that both RAREs are probably recognized independently of the developmental stage.

Discussion

Most ASD studies highlight a strong genetic heterogeneity where both de novo germline and rare inherited variants are distributed across numerous genes yet, interconnected in similar...
biological processes such as chromatin remodeling and transcription regulation [8,10–13,16] or target of fragile X mental retardation protein (FMRP) [59]. Furthermore, previous WES studies associate genes to ASD only if two or more disrupting variants are observed in the same gene in different individuals. Variant and gene association depends uniquely on the effect the affected gene has [6,10–13,15,59], though it is also important to examine how two or more de novo variants in the same individual might play a synergic role on ASD phenotype. Moreover, every result given by WES or WGS trio studies should be carefully analyzed, as it might be an incidental finding unless function studies are performed.

The findings of RAREs sequences in the promoter regions, in humans as in mice, made us consider that RARs family might regulate FOXN1 and ALDH1A3 genes. Thus, we aimed to determine if any of those RAREs predicted might be functional using mice as models. We first confirm expression of Aldh1a3 in PC during in adult (~P30) mouse brain as previously shown [56] and evaluated co-expression of Foxn1 in the same region and stage. Moreover, we demonstrate that both genes are also expressed in embryo (~E13.5) mice. ChIP-PCR results suggest that Foxn1 and Aldh1a3 expression is promoted by Rarb binding to different RAREs in both tissues (adult PC and embryo whole brain; Fig 2B, Table 3). Since ChIP was only carried out to analyze Rarb-RARE interaction, we could not assure that any other members of the RAR family or other transcription factors might contribute to Foxn1 or Aldh1a3 regulation during the stages analyzed. Therefore, it is possible that gene RA regulation is exerted by other proteins in both tissues at both stages. Based on known functions of RARs/RXRs, these results predict a possible positive regulation by Rarb for both genes. The RA regulation model predicts that in RA presence, RARs/RXRs release co-repressor proteins and recruit co-activation complexes [34]. In fact, it has been demonstrated that RA promotes Rars binding to putative RAREs in mouse embryonic stem cells working as transcription enhancers [60]. As Rarb and the other RAR family members regulate many genes at different stages and tissues at time-specific periods, lack of RA might contribute to a transcriptional deregulation.

Recently, non functional ALDH1A3 alleles have been reported as responsible for ophthalmologic diseases as A/M in which four of the six reports mention that some affected individuals also have ASD like features or intellectual disability in different degrees, even though these findings are generally considered as incidental [18,19,21,23]. However, it is not possible to discard the idea that mutations in ALDH1A3 might alter brain development since it has been described that RA is essential for brain cortex development facilitating transcription of essential genetic markers [61]. Additionally, FAM07 child carries a non-synonymous variant, predicted to be pathogenic in ALDH1A3 (Table 2). One would thus predict that RA synthesis and concentration in basal ganglia, nucleus accumbens, striatum, and PC would be lower than normal levels.

Since RA mediates transcription of different genes, variants in ALDH1A3 in conjunction with other inherited rare variants or de novo variants potentially act synergistically causing ASD. This might also be the case in the A/M phenotype where some of the affected individuals also have ASD or intellectual disability [19]. Yet, if another pathogenic variant is present on a gene that is regulated by retinoic acid, the altered concentrations levels of RA together with a deficient function of a second gene might end up in a phenotype such as ASD. As no clear data of FOXN1 regulation of brain development is clear, we cannot predict a direct effect of the non-synonymous variant observed in this child. Since this nuclear receptor is apparently regulated by RA via Rarb, the lack of this metabolite due to the mutation in ALDH1A3 might cause a lower transcription of FOXN1, leading to a dysregulation of genes and pathways not yet described. Moreover, nude affected humans by mutations or truncations in the FOXN1 gene do not present gross central nervous system alterations [62], but they however present changes in the corpus callosum, neural tube and choroid plexus [33,62]. This
suggest that FOXN1 has similar functions as other member of the FOX family like FOXP1 and FOXP2 [63,64], which have been already associated to ASD [6].

In conclusion, the results indicate that next generation sequencing from under-studied cohorts provide new genetic data that might conduct to new perspectives and hypothesis to explain genetic basis of ASD. Our results are in concordance with previous studies demonstrating that transcription factors play significant roles in ASD [8,10–13,16]. A previous study of our group reported that genes involved in transcription regulation are essential to serotoninergic pathway stability in depression [65]. Moreover, even though ASD is highly heritable, a multitude of environmental influences play a fundamental role on ASD incidence [4], which might interact with the proband’s genetic variants causing the disorder. Though carrying a variant in one allele of ALDH1A3 might not cause a defined phenotype such as A/M, this can act as a risk allele to ASD since lower levels of RA might contribute to a poor transcription of several genes, one of them being FOXN1. Additionally, the second gene variant present in FOXN1, might affect this transcription factor’s function by not properly regulating yet uncovered pathways in brain. Finally, when attributing causation to de novo variants prudence needs to be exercised.

Supporting Information

S1 Table. Retinoic Acid Response Elements (RAREs) found 30000bp upstream and 1000bp downstream from the initial transcription site in both DNA strands for ALDH1A3 and FOXN1 genes in humans, and Aldh1a3 and Foxn1 genes in mice. Relative positions are given from the initial transcription site of each gene.

S2 Table. Primer sequences flanking conserved regions of Aldh1a3 and Foxn1 transcripts in mice. Sequences are given 5’→3’ direction.

S3 Table. Primer sequences used to amplify each flanking RARE bioinformatically predicted sequences for Aldh1a3 and Foxn1 genes in mice. Sequences are given 5’→3’ direction.

Acknowledgments

We thank the children, their families for deciding to be part of this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Liga Colombiana de Autismo participant’s member list is as follows: Edith B. Roncancio, Camilo O. Vargas, Francisco J. Paredes, Sandra M. Grisales, Anyela M. Peña, Miguel A. Robayo, María E. Rodriguez and María E. Reyes.

Author Contributions

Conceived and designed the experiments: MCL OAM NBH. Performed the experiments: OAM AMO. Analyzed the data: OAM MCL. Contributed reagents/materials/analysis tools: NBH MCL. Wrote the paper: OAM MCL NBH. Patient referral, clinical and psychological evaluation: Liga Colombiana de Autismo.

References


